Case Studies

Displaying 1 - 12 of 356
YNHHS Main Campus

Let’s conduct a quick thought experiment. We enter a time machine and set the controls for Connecticut in 2015. As luck would have it, we land in a meeting room of the imaging department at the Yale-New Haven Health system. There we overhear a conversation. Imaging aficionados that we are, we quickly realize two groups are present—IT leaders and ranking radiologists. It’s hard to make out the exact words through the time warp. However, we clearly hear one term repeated several times: “deconstructed PACS.” 

cardiologist patient heart compensation starting salary 2022 interventional cardiologist

TAVR is increasingly seen as the preferred option for symptomatic severe aortic stenosis, and clinical guidelines in the U.S. reserve their highest recommendations for patients who experience symptoms. Asymptomatic patients, meanwhile, are typically managed by clinical surveillance or a “watch and wait” approach; no symptoms means no treatment.

Fresenius Kabi Header

As the leading provider of generic contrast agents, Fresenius Kabi’s commitment is to provide you with choice and value – by continuing to grow their radiology portfolio. We look forward to seeing you at RSNA 2025 | Booth #3247 | South Hall 

Canon Medical is launching new X-ray advances at the Radiological Society of North America (RSNA) 2025 annual meeting. This includes the advanced artificial intelligence Clear-IQ technology to boost diagnostic image quality of low-dose images, and the new Adora DRFi low-dose fluoroscopy system. Canon will also highlight the patented technology built into its premium mobile X-ray solution, the SOLTUS 500.

Canon Medical is launching new X-ray advances at the Radiological Society of North America (RSNA) 2025 annual meeting.

Samuel Horr

Pulmonary embolism (PE) treatment has evolved over time, yet it remains the third leading cause of cardiovascular death across the United States. TriStar Health, a comprehensive health system serving Tennessee and Kentucky and part of HCA Healthcare, is now using an AI platform to support clinicians in providing more effective care for PE patients.

MRI Scans

Six years ago, two radiologists with dissimilar backgrounds and divergent clinical interests put their heads together and launched a new practice. One physician was an academic subspecialized in musculoskeletal reads. The other, a private practitioner, concentrated on oncologic imaging. That’s how Transparent Imaging was born, powered by Konica Minolta. 

heart data research doctor cardiologist AI

Identifying the signs of severe aortic stenosis is typically a fairly straightforward process for cardiologists. In some cases, however, the patient’s symptoms present in a way that is outside of the norm. 

doctor patient elderly check up hospital

Prosthesis-patient mismatch (PPM) is the phenomenon that occurs when the effective orifice area of a prosthetic heart valve isn’t adequately sized to meet a patient’s blood flow requirements. More is known today about PPM than ever before—but there is still so much to learn. 

Dinner Party

In a private dining room in Miami, something unusual is happening. Leaders from competing imaging centers are openly discussing their best practices—even sharing vendor recommendations and operational strategies that have doubled their volumes while cutting costs in half.

centennial

Pulmonary embolism (PE) remains one of the leading causes of cardiovascular death in the United States. TriStar Health, part of HCA Healthcare, has made PE a priority by bringing together a multidisciplinary team and adopting AI-enabled workflows to support timely diagnosis and treatment. This approach is designed to drive consistent, high-quality care – whether patients are seen at a large hospital or a community ER.

Konica Minolta

Market-savvy radiologists recognize the shortage of talent in their profession as a challenging yet exciting opportunity. More patients and referrers are ready to be served—and greater compensation is ripe to be earned.  

Doctor with patient

Atrial fibrillation (AFib), the most common heart rhythm disorder, continues to rise globally - it is predicted to affect more than 12 million people in the US by 2030 and almost 18 million people in Europe by 2060. With a growing aging population and an increased prevalence of heart disease, the demand for effective treatments for AFib is higher than ever before.